BR112015005384A2 - neurotoxinas clostridium botuliem recombinantes - Google Patents
neurotoxinas clostridium botuliem recombinantesInfo
- Publication number
- BR112015005384A2 BR112015005384A2 BR112015005384A BR112015005384A BR112015005384A2 BR 112015005384 A2 BR112015005384 A2 BR 112015005384A2 BR 112015005384 A BR112015005384 A BR 112015005384A BR 112015005384 A BR112015005384 A BR 112015005384A BR 112015005384 A2 BR112015005384 A2 BR 112015005384A2
- Authority
- BR
- Brazil
- Prior art keywords
- botuliem
- neurotoxins
- contiguous nucleotide
- recombinant clostridium
- nucleotide sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201219602A GB201219602D0 (en) | 2012-10-31 | 2012-10-31 | Recombinant clostridium botulinum neurotoxins |
| PCT/GB2013/052845 WO2014068317A1 (en) | 2012-10-31 | 2013-10-31 | Recombinant clostridium botulinum neurotoxins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015005384A2 true BR112015005384A2 (pt) | 2017-08-08 |
Family
ID=47358958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015005384A BR112015005384A2 (pt) | 2012-10-31 | 2013-10-31 | neurotoxinas clostridium botuliem recombinantes |
Country Status (26)
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| PT3274364T (pt) * | 2015-03-26 | 2021-11-05 | Harvard College | Neurotoxina botulínica manipulada |
| WO2017063743A1 (en) | 2015-10-14 | 2017-04-20 | Merz Pharma Gmbh & Co. Kgaa | Improvements to ultrasound-based therapy of photoaged tissue |
| CA3010146A1 (en) | 2016-03-02 | 2017-09-08 | Merz Pharma Gmbh & Co. Kgaa | Composition comprising botulinum toxin |
| EP3263710A1 (en) * | 2016-07-01 | 2018-01-03 | Ipsen Biopharm Limited | Production of activated clostridial neurotoxins |
| JP7100020B2 (ja) | 2016-08-24 | 2022-07-12 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作されたボツリヌス神経毒素 |
| SI3432916T1 (sl) | 2016-09-13 | 2020-01-31 | Allergan, Inc. | Stabilizirani ne-protein klostridijski toksin sestavki |
| US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
| ES2930237T3 (es) | 2017-07-06 | 2022-12-09 | Merz Pharma Gmbh & Co Kgaa | Neurotoxinas botulínicas recombinantes nuevas con mayor duración de efectos |
| SG11202003229RA (en) | 2017-10-11 | 2020-05-28 | Illustris Pharmaceuticals Inc | Methods and compositions for topical delivery |
| CN119020332A (zh) * | 2018-01-29 | 2024-11-26 | 益普生生物制药有限公司 | 切割非神经元snare的肉毒杆菌神经毒素 |
| WO2019158745A1 (de) * | 2018-02-16 | 2019-08-22 | Bontana Therapies Gmbh | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
| GB201815844D0 (en) * | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| GB202011055D0 (en) | 2020-07-17 | 2020-09-02 | Ipsen Bioinnovation Ltd | Treatment of post-operative pain |
| GB202015618D0 (en) * | 2020-10-01 | 2020-11-18 | Ipsen Biopharm Ltd | Method for producing beta-trypsin |
| CN115819526A (zh) * | 2022-12-02 | 2023-03-21 | 海雅美生物技术(珠海)有限公司 | 一种重组肉毒杆菌神经毒素及其制备方法和应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
| NZ308772A (en) * | 1995-05-17 | 1999-04-29 | Du Pont | Recombinant baculovirus insecticides |
| WO2000002524A2 (en) | 1998-07-10 | 2000-01-20 | U.S. Army Medical Research Institute Of Infectious Diseases | Botulinum neurotoxin vaccine |
| ES2277854T5 (es) * | 1999-08-25 | 2011-02-04 | Allergan, Inc. | Neurotoxinas recombinantes activables. |
| US7374896B2 (en) | 2001-08-28 | 2008-05-20 | Allergan, Inc. | GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity |
| US7354740B2 (en) * | 2003-09-25 | 2008-04-08 | Allergan, Inc. | Animal product free system and process for purifying a botulinum toxin |
| US20110111483A1 (en) | 2004-06-30 | 2011-05-12 | Allergan, Inc. | Optimizing Expression of Active Botulinum Toxin Type E |
| EP1761558A1 (en) * | 2004-06-30 | 2007-03-14 | Allergan, Inc. | Optimizing expression of active botulinum toxin type e |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| DE102004043009A1 (de) * | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005002978B4 (de) | 2005-01-21 | 2013-04-25 | Merz Pharma Gmbh & Co. Kgaa | Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form |
| CA2610103A1 (en) * | 2005-09-19 | 2007-03-19 | Allergan, Inc. | Clostridial toxin activatable clostridial toxins |
| US20070218084A1 (en) * | 2005-12-30 | 2007-09-20 | Fondazione Pierfranco E Luisa Mariani- Onlus | Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy |
| CA2657521A1 (en) * | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| WO2009014854A1 (en) * | 2007-07-26 | 2009-01-29 | Allergan, Inc. | Methods of activiting clostridial toxins |
| CN105833254A (zh) | 2008-12-10 | 2016-08-10 | 阿勒根公司 | 梭菌毒素药物组合物 |
| GB0903006D0 (en) * | 2009-02-23 | 2009-04-08 | Syntaxin Ltd | Modified non-cytotoxic proteases |
| AU2010236613B2 (en) * | 2009-04-14 | 2016-07-07 | Mcw Research Foundation, Inc. | Engineered botulinum neurotoxin |
| CA2784666A1 (en) * | 2009-12-16 | 2011-11-17 | Allergan, Inc. | Modified clostridial toxins comprising an integrated protease cleavage site-binding domain |
| WO2012112434A1 (en) | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Inhibiting aberrant blood vessel formation using retargeted endopeptidases |
| GB201219602D0 (en) * | 2012-10-31 | 2012-12-12 | Syntaxin Ltd | Recombinant clostridium botulinum neurotoxins |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| JP7100020B2 (ja) * | 2016-08-24 | 2022-07-12 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作されたボツリヌス神経毒素 |
-
2012
- 2012-10-31 GB GB201219602A patent/GB201219602D0/en not_active Ceased
-
2013
- 2013-10-31 PL PL13811605T patent/PL2914282T3/pl unknown
- 2013-10-31 TW TW107110108A patent/TWI673361B/zh not_active IP Right Cessation
- 2013-10-31 PT PT138116058T patent/PT2914282T/pt unknown
- 2013-10-31 KR KR1020157010099A patent/KR102188539B1/ko active Active
- 2013-10-31 EA EA201590794A patent/EA201590794A8/ru unknown
- 2013-10-31 CA CA2885519A patent/CA2885519A1/en not_active Abandoned
- 2013-10-31 NZ NZ705575A patent/NZ705575A/en not_active IP Right Cessation
- 2013-10-31 EP EP20153122.5A patent/EP3673914B1/en active Active
- 2013-10-31 US US14/427,234 patent/US10030238B2/en active Active
- 2013-10-31 HU HUE13811605A patent/HUE036764T2/hu unknown
- 2013-10-31 WO PCT/GB2013/052845 patent/WO2014068317A1/en active Application Filing
- 2013-10-31 MX MX2015005156A patent/MX367080B/es active IP Right Grant
- 2013-10-31 TW TW108125708A patent/TW202012622A/zh unknown
- 2013-10-31 DK DK13811605.8T patent/DK2914282T3/en active
- 2013-10-31 ES ES13811605.8T patent/ES2662402T3/es active Active
- 2013-10-31 ES ES17201198T patent/ES2788199T3/es active Active
- 2013-10-31 AR ARP130103981A patent/AR093309A1/es active IP Right Grant
- 2013-10-31 NO NO13811605A patent/NO2914282T3/no unknown
- 2013-10-31 TW TW102139558A patent/TWI626307B/zh not_active IP Right Cessation
- 2013-10-31 DK DK17201198.3T patent/DK3326644T3/da active
- 2013-10-31 HU HUE17201198A patent/HUE048802T2/hu unknown
- 2013-10-31 KR KR1020207026658A patent/KR102264478B1/ko active Active
- 2013-10-31 SG SG10201701140WA patent/SG10201701140WA/en unknown
- 2013-10-31 EP EP13811605.8A patent/EP2914282B1/en active Active
- 2013-10-31 PL PL17201198T patent/PL3326644T3/pl unknown
- 2013-10-31 CN CN201380047542.8A patent/CN104755098A/zh active Pending
- 2013-10-31 UA UAA201502159A patent/UA118837C2/uk unknown
- 2013-10-31 CN CN201910795176.3A patent/CN110499321A/zh active Pending
- 2013-10-31 SG SG11201502372SA patent/SG11201502372SA/en unknown
- 2013-10-31 IN IN436MUN2015 patent/IN2015MN00436A/en unknown
- 2013-10-31 AU AU2013340610A patent/AU2013340610B2/en not_active Ceased
- 2013-10-31 BR BR112015005384A patent/BR112015005384A2/pt not_active Application Discontinuation
- 2013-10-31 PT PT172011983T patent/PT3326644T/pt unknown
- 2013-10-31 EP EP17201198.3A patent/EP3326644B1/en active Active
-
2015
- 2015-03-03 ZA ZA2015/01449A patent/ZA201501449B/en unknown
- 2015-03-08 IL IL237623A patent/IL237623B/en active IP Right Grant
- 2015-04-23 MX MX2019009222A patent/MX2019009222A/es unknown
-
2018
- 2018-05-21 AU AU2018203556A patent/AU2018203556B2/en not_active Ceased
- 2018-12-10 JP JP2018230980A patent/JP2019068823A/ja not_active Ceased
-
2019
- 2019-12-26 AR ARP190103867A patent/AR117738A2/es unknown
-
2020
- 2020-02-05 JP JP2020017612A patent/JP2020078321A/ja active Pending
- 2020-09-30 AU AU2020244481A patent/AU2020244481A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015005384A2 (pt) | neurotoxinas clostridium botuliem recombinantes | |
| BR112012033699A2 (pt) | polipeptídeo tendo atividade beta-glicosidase e seus usos | |
| BR112012033703A2 (pt) | polipeptídeo tendo atividade beta-glicosidase e seus usos | |
| MY176331A (en) | Carbohydrate degrading polypeptide and uses thereof | |
| WO2014202616A3 (en) | Rasamsonia gene and use thereof | |
| BR112012033404A2 (pt) | polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos. | |
| BR112015031639A2 (pt) | integração alvo | |
| EA201291024A1 (ru) | Композиции эндорибонуклеаз и способы их использования | |
| BR112014019601A2 (pt) | método para a produção de uma planta tendo uma resistência melhorada à seca, usos de uma sequência de aminoácido, de pelo menos uma parte de uma sequência de ácido nucleico, de uma proteína, e de uma planta, célula de planta, ou produto de planta, e, planta, célula de planta ou produto de planta | |
| BRPI1015536A2 (pt) | polipeptídeo de degradação de carboidratos e usos do mesmo | |
| BR112013010551A2 (pt) | variantes de isopreno sintase para a produção aprimorada de isopreno | |
| BR112013004124A2 (pt) | peptídeo ou complexo de peptídeos ligando a alfa2 integrina e métodos e utilizações envolvendo os mesmos | |
| BR112014006009A2 (pt) | variantes de enzimas com propriedades aperfeiçoadas | |
| BR112016002494A2 (pt) | Proteí-nas construídas com um sítio de clivagem de protease, ácido nucléico, vetor, célula e processo de engenharia de uma proteína recombinante e de um grande número de variantes de ácidos nucleicos que codificam proteínas recombinantes | |
| BR112015017797A2 (pt) | celobio-hidrolase termoestável | |
| BR112013027641A2 (pt) | processo verde para produzir poli-hidroxialcanoatos e produtos químicos com o uso de uma matéria-prima renovável | |
| BR112014021993A2 (pt) | detecção da variação de nucleotídeo em sequência de ácido nucleico alvo através de ensaio de clivagem e extensão de pto | |
| EA201300056A1 (ru) | Полипептид с активностью ацетилксиланэстеразы и его применения | |
| MX365095B (es) | Métodos y composiciones para incrementar la producción de ácido siálico y tratar condiciones de enfermedades relacionadas siálicas. | |
| BR112014019593A2 (pt) | método para a produção de uma planta tendo uma resistência melhorada à seca, e, usos de uma sequência de aminoácido, de pelo menos uma parte de uma sequência de ácido nucleico, de uma proteína, e de uma planta, célula de planta, ou produto de planta, e, planta, célula de planta ou produto de planta | |
| BR112012033396A2 (pt) | Polipetídeo tendo atividade swollenin e seus usos. | |
| BR112014010053A2 (pt) | variantes de isopreno sintase com solubilidade aprimorada para produção de isopreno | |
| WO2014044626A3 (en) | Process for producing gelatin employing aspergillopepsin ii | |
| BR112014008315A2 (pt) | polipeptídeos da cbh i variante com inibição pelo produto reduzida | |
| BR112018001855A2 (pt) | expressão de enzimas beta-xilosidase recombinantes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B25D | Requested change of name of applicant approved |
Owner name: IPSEN BIOPHARM LIMITED (GB) , IPSEN BIOINNOVATION |
|
| B25G | Requested change of headquarter approved |
Owner name: IPSEN BIOPHARM LIMITED (GB) ; IPSEN BIOINNOVATION |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 38/48 , C07K 14/33 Ipc: C12N 9/52 (2006.01), A61K 38/48 (2006.01), C07K 14 |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |